Related Experiment Video
Updated: Jul 10, 2025

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
[Management of Cast Nephropathy]
Emanuele De Simone1, Roberta Fenoglio1, Simone Cortazzi1
1University Center of Excellence on Nephrological, Rheumatological and Rare Diseases (ERK-net, ERN-Reconnect and RITA-ERN Member) including Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley (North-West Italy), San Giovanni Bosco Hub Hospital, ASL Città di Torino and Department of Clinical and Biological Sciences of the University of Turin, Turin, Italy.
Myeloma cast nephropathy, a common cause of kidney injury in multiple myeloma patients, is primarily managed with clone-based therapy to reduce light chain production. Adjuvant strategies include increasing urine flow and alkalinization, while extracorporeal light chain removal remains under investigation.
Area of Science:
- Nephrology
- Hematology
- Oncology
Context:
- Myeloma cast nephropathy is the leading cause of acute kidney injury in multiple myeloma.
- Current management focuses on reducing light chain production and precipitation.
Purpose:
- To review the management of myeloma cast nephropathy.
- To discuss the role of adjuvant therapies and extracorporeal light chain removal.
Summary:
- Clone-based therapy is the mainstay for reducing light chain production.
- Adjuvant therapy involves promoting high urine volume and alkalinization.
- The efficacy of extracorporeal light chain removal requires further investigation, potentially influenced by membrane safety and cost.
Impact:
- Highlights the importance of clone-based therapy in managing myeloma cast nephropathy.
- Underscores the need for further research into extracorporeal removal methods.
- Suggests that cost-effective and safe membranes could improve the utility of extracorporeal therapies.
More Related Videos
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
07:38Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
Published on: May 6, 2018
Related Concept Videos
Dialysis
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Nephrons
Heart Failure Drugs: Diuretics
Chronic Pancreatitis II: Collaborative Care
Assessment: